ARCT - Arcturus Therapeutics: Strategic opportunities beyond CSL
Arcturus Therapeutics is facing challenges with its collaboration with CSL regarding the KOSTAIVE Covid-19 vaccine, with CSL writing off $430 million related to the agreement and arbitration ongoing over milestone payments. This situation creates strategic opportunities for Arcturus to pivot towards new collaboration partners like Sanofi or BioNTech, who are looking to advance their mRNA vaccine pipelines. Despite current low investor confidence and declining revenue from the CSL agreement, Arcturus possesses valuable advanced RNA technology and a pipeline including rare disease programs, which could significantly increase its market capitalization through new partnerships.
How (ARCT) Movements Inform Risk Allocation Models
This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, highlighting weak sentiment across all time horizons and an exceptional 232.5:1 risk-reward setup. It outlines three trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis for support and resistance levels. The report emphasizes the potential for a 74.3% gain against a 0.3% risk based on current signals.
Arcturus Therapeutics Holdings Inc (NQ: ARCT) News
This article provides recent news headlines concerning Arcturus Therapeutics Holdings Inc (ARCT), primarily focusing on analyst ratings and the company's stock performance and COVID-19 vaccine developments in August 2021. Key updates include positive interim results for a Phase 1 trial, an mRNA COVID-19 vaccine update, and the company receiving approval for vaccine candidates and establishing a manufacturing plant in Vietnam.
Arcturus Therapeutics Holdings Inc (NQ: ARCT)
This page provides a collection of recent news headlines and articles related to Arcturus Therapeutics Holdings Inc. (ARCT), focusing on topics such as Q4 earnings, growth investment opportunities, analyst ratings, and biotech stock performance. The articles span from July 2023 to March 2024, highlighting ARCT's financial performance, pipeline potential, and analyst insights.
HC Wainwright & Co. Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation
HC Wainwright & Co. has reiterated its Neutral rating on Arcturus Therapeutics Holdings (ARCT). This indicates that the analyst firm does not foresee significant upward or downward movement for the stock in the near term. Investors often look to such ratings for an independent assessment of a company's financial health and stock potential.
HC Wainwright & Co. Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation
This article reports that HC Wainwright & Co. has reiterated its Neutral rating on Arcturus Therapeutics Holdings (ARCT). The rating was maintained by analyst Joseph Pantginis. The content of the report is not provided.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Arcturus Therapeutics Holdings Inc. recently reported first-quarter results that fell short of revenue expectations, leading analysts to revise down their forecasts. The consensus for 2026 now projects a significant revenue decline to US$15.7m and increased losses of US$4.20 per share. This negative outlook has caused the consensus price target to drop by 12% to US$20.40, indicating growing pessimism about the company's intrinsic value.
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $21
CCORF has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) and maintained its target price of $2
Biotechnology company Arcturus Therapeutics Holdings Inc. recently announced through a filing with the U.S. Securities and Exchange Commission (SEC) that Mr. Dennis Mulroy has been officially appointed as the company's Chief Financial Officer (CFO), eff
Arcturus Therapeutics Holdings Inc., a biotechnology company, has announced the appointment of Dennis Mulroy as its new Chief Financial Officer (CFO), effective May 1, 2026. This appointment, disclosed in an SEC filing and approved by the board, signifies a strategic deployment to strengthen the company's financial management. Mulroy will oversee financial planning, capital management, investor relations, and compliance, providing crucial financial support for Arcturus's mRNA therapies and vaccine development.
ARK/ Cathie Wood report 2.95M shares in Arcturus (ARCT)
ARK Investment Management LLC and Catherine D. Wood have reported beneficial ownership of 2,947,556 shares of Arcturus Therapeutics Holdings Inc. (ARCT), representing a 10.37% stake in the company. This disclosure was made in an amended Schedule 13G/A filing with the SEC, dated May 7, 2026. ARK holds sole voting and dispositive power over these shares, while Catherine D. Wood possesses shared voting and dispositive power over the same amount.
Earnings call transcript: Arcturus Therapeutics Q1 2026: EPS Beat, Revenue Decline
Arcturus Therapeutics reported a Q1 2026 EPS beat, exceeding forecasts by 15.18% with -0.95 USD despite a revenue decline. The company is strategically shifting its focus to rare disease clinical programs, moving away from partnership income, which led to the revenue decrease. Leadership highlighted strong cash reserves extending through Q2 2028, providing financial flexibility for ongoing investments in its mRNA therapeutic pipeline.
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics has announced its financial results for Q1 2026, alongside significant pipeline advancements in its rare disease programs. The company has initiated enrollment for a Phase 2 study of its inhaled mRNA therapeutic for Cystic Fibrosis (ARCT-032) and received FDA regulatory direction for its ornithine transcarbamylase (OTC) deficiency program (ARCT-810), securing a path toward a pivotal pediatric trial. Arcturus reports a cash position of $213.4 million, providing a runway extending beyond Q2 2028, and has strengthened its executive team with new Chief Medical and Financial Officers.
Q1 2026 Arcturus Therapeutics Holdings Inc Earnings Call Transcript
This article provides the Q1 2026 earnings call transcript for Arcturus Therapeutics Holdings Inc. The call began with an introduction by Neda Safarzadeh, Vice President, Head of Investor Relations, Public Relations and Marketing, followed by remarks from Joe Payne, President and CEO, Dr. Alan Cohen, Chief Medical Officer, and Dennis Mulroy, Chief Financial Officer. The transcript details the opening statements and the initial part of the earnings call.
Biotechnology company Arcturus Therapeutics Holdings Inc. recently announced through a filing with the U.S. Securities and Exchange Commission (SEC) that Mr. Dennis Mulroy has been officially appointed as the company's Chief Financial Officer (CFO), eff
Arcturus Therapeutics Holdings Inc., a biotechnology company, has announced the appointment of Dennis Mulroy as its new Chief Financial Officer (CFO), effective May 1, 2026. This appointment was disclosed in an SEC filing and signifies a strategic move to bolster the company's financial management. Mulroy will be responsible for financial planning, capital management, investor relations, and compliance, supporting the company's focus on mRNA therapies and vaccine development.
Arcturus Therapeutics (NASDAQ: ARCT) Q1 2026 hit by 93% revenue drop
Arcturus Therapeutics reported a significant 93% drop in Q1 2026 revenue to $2.1 million, down from $29.4 million a year earlier, primarily due to reduced collaboration revenue from CSL Seqirus and lower BARDA grant revenue. Despite the revenue decline, operating expenses decreased, narrowing the cash burn though the net loss widened to $27.0 million. The company ended the quarter with $213.4 million in cash, which is expected to fund operations for at least the next twelve months, as it continues to advance its rare-disease RNA therapeutic candidates ARCT-032 and ARCT-810.
[Form 3] Arcturus Therapeutics Holdings Inc. Initial Statement of Beneficial Ownership
Arcturus Therapeutics Holdings Inc. has filed an initial Form 3 for its Chief Financial Officer, Dennis Mulroy, establishing a baseline statement of beneficial ownership. The filing indicates no reportable transactions or derivative positions, nor any existing holdings, serving purely as a foundational declaration of ownership status for the CFO. This is a neutral filing, with no positive or negative impact on the stock mentioned.
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics announced its Q1 2026 financial results, highlighting progress in its rare disease pipeline. Key advancements include initiating enrollment for a Phase 2 cystic fibrosis study ahead of schedule and receiving FDA guidance for its OTC deficiency program, allowing a clear path to a pivotal pediatric trial. The company also reported a strong cash position of $213.4 million, providing a cash runway extending beyond Q2 2028, and announced the appointments of a new Chief Medical Officer and Chief Financial Officer.
Revenue plunge and leadership change at Arcturus (NASDAQ: ARCT)
Arcturus Therapeutics reported a significant widening of its Q1 2026 net loss to $27.0 million from $14.1 million year-over-year, alongside a sharp revenue decline to $2.1 million from $29.4 million, as the company shifts focus from infectious disease vaccines to rare disease programs. Despite the financial setbacks, the company maintains a cash runway beyond Q2 2028 and made pipeline progress in cystic fibrosis and ornithine transcarbamylase deficiency. Additionally, Arcturus appointed Dennis Mulroy as its new Chief Financial Officer, detailing his compensation package and outlining his role in the company's financial strategy.
Biotechnology company Arcturus Therapeutics Holdings Inc. recently announced through a filing with the U.S. Securities and Exchange Commission (SEC) that Mr. Dennis Mulroy has been officially appointed as the company's Chief Financial Officer (CFO), eff
Arcturus Therapeutics Holdings Inc. has appointed Dennis Mulroy as its new Chief Financial Officer, effective May 1, 2026. This appointment, disclosed in an SEC filing, aims to strengthen the biotechnology company's financial management as it focuses on mRNA therapies and vaccine development. Mulroy will oversee financial planning, capital management, investor relations, and compliance.
Arcturus Therapeutics (ARCT) Projected to Post Earnings on Thursday
Arcturus Therapeutics (NASDAQ:ARCT) is projected to report its Q1 2026 earnings on Thursday, May 7th, with analysts forecasting a loss of ($1.0133) per share and revenue of $6.296 million. The company previously missed estimates and has a significantly negative net margin. Despite a "Moderate Buy" consensus and an average price target of $29.50, institutional investors own a large portion of the stock.
Arcturus Therapeutics Holdings (Nasdaq:ARCT) - Stock Analysis
Arcturus Therapeutics Holdings (ARCT) is a messenger RNA medicines company with a market cap of US$238.8m, noted for being 84.3% undervalued by a high-target analyst, though another finds it overvalued by 7.8%. The company is currently unprofitable but forecasts revenue growth of 21.88% per year. Recent analyst commentary shows a mix of cautious and constructive views, with price targets adjusted based on program execution, Q4 commentary, and pipeline progress in cystic fibrosis and ornithine transcarbamylase deficiency.
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
Arcturus Therapeutics Holdings Inc. announced it will release its first-quarter financial results for the period ended March 31, 2026, after market close on Thursday, May 7, 2026. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss the results and provide a corporate update. Arcturus Therapeutics is a messenger RNA medicines company focusing on rare liver and respiratory diseases.
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
Arcturus Therapeutics Holdings Inc. announced it will release its first quarter 2026 financial results after market close on Thursday, May 7, 2026. The company will also host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a corporate update. Arcturus is a messenger RNA medicines company focusing on liver and respiratory rare disease therapeutics.
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
Arcturus Therapeutics Holdings Inc. announced it will release its financial results for the first quarter ended March 31, 2026, after the market closes on Thursday, May 7, 2026. The company will also host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to provide a corporate update. Arcturus is a messenger RNA medicines company focusing on liver and respiratory rare disease therapeutics, known for developing KOSTAIVE®, the first self-amplifying mRNA COVID vaccine.
How Arcturus Therapeutics Holdings Inc. (ARCT) Affects Rotational Strategy Timing
This article analyzes Arcturus Therapeutics Holdings Inc. (ARCT) using AI models to provide trading strategies. It identifies a mid-channel oscillation pattern and highlights a significant risk-reward setup. Key findings indicate weak near-term and long-term sentiment but mid-term strength, offering specific entry, target, and stop-loss levels for different trading profiles.
ARCT Price Today: Arcturus Therapeutics Holdings Inc. Stock Price, Quote & Chart | MEXC
This article provides detailed real-time stock information for Arcturus Therapeutics Holdings Inc. (ARCT), including its current price, market capitalization, daily trading ranges, and performance trends over various periods. It also outlines steps on how to buy ARCT stock on MEXC and offers an FAQ section covering company classification, profitability metrics, and dividend information.
Arcturus (NASDAQ: ARCT) schedules 2026 virtual meeting on pay, board and auditor
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has scheduled its 2026 annual shareholder meeting for June 5, 2026, at 9:00 a.m. Pacific Time, to be held virtually. Shareholders will vote on the election of eight directors, the approval of executive officer compensation on an advisory basis, and the ratification of Deloitte & Touche LLP as the independent auditor for 2026. The proxy statement details compensation, governance, and audit-related information, emphasizing the company's commitment to pay-for-performance and shareholder alignment.
Arcturus Therapeutics Holdings (ARCT) price target decreased by 27.17% to 25.78
This article reports that the price target for Arcturus Therapeutics Holdings (ARCT) has been decreased by 27.17%, setting the new target at $25.78.
Arcturus Therapeutics Holdings (NasdaqGM:ARCT) Stock Forecast & Analyst Predictions
Arcturus Therapeutics Holdings (ARCT) is forecast to grow earnings by 10.9% and revenue by 21.9% per annum, although it is expected to remain unprofitable over the next three years with a forecast return on equity of -318.3%. Recent analyst updates show mixed views, with some lowering price targets due to Q4 results and changes in COVID-related profit expectations, while others maintain confidence in the company's clinical pipeline for cystic fibrosis and ornithine transcarbamylase deficiency programs. The company's revenue growth is projected to outpace the US market.
Diversify Advisory Services LLC Sells 115,500 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
Diversify Advisory Services LLC significantly reduced its stake in Arcturus Therapeutics Holdings Inc. by selling 115,500 shares, retaining only 15,000 shares worth $92,000. This divestment follows Arcturus's disappointing Q4 earnings, which missed both EPS and revenue expectations, and the company continues to show negative margins. Despite a consensus "Moderate Buy" rating, some analysts have sharply cut price targets, reflecting mixed sentiment.
(ARCT) and the Role of Price-Sensitive Allocations
This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, identifying strong near and mid-term sentiment with a weak long-term outlook. It highlights a significant 248.0:1 risk-reward setup, targeting a 69.0% gain. The piece also outlines three distinct institutional trading strategies for different risk profiles: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of "Moderate Buy" from Brokerages
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received a consensus "Moderate Buy" rating from thirteen brokerages, with an average 12-month price target of $29.50. Despite recent mixed results including a missed earnings estimate and some price target cuts, other firms have initiated coverage with buy ratings, contributing to the overall positive outlook. Institutional investors hold approximately 94.54% of the company's shares.
HC Wainwright & Co. Downgrades Arcturus Therapeutics Holdings (ARCT)
HC Wainwright & Co. has downgraded Arcturus Therapeutics Holdings (ARCT) stock. This indicates a revised, more cautious outlook from the financial firm regarding the company's future performance. Investors and market watchers should note this change in analyst sentiment.
HC Wainwright & Co. Downgrades Arcturus Therapeutics Holdings (ARCT)
HC Wainwright & Co. has downgraded its rating for Arcturus Therapeutics Holdings (ARCT). This downgrade indicates a less optimistic outlook from the financial firm regarding the company's stock performance. Investors will likely monitor ARCT's future developments and financial reports following this analyst action.
Responsive Playbooks and the ARCT Inflection
This article provides an in-depth analysis of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), highlighting strong near and mid-term sentiment but a weak long-term outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with specific entry, target, and stop-loss zones. The analysis also covers multi-timeframe signal strengths, support, and resistance levels for ARCT.
Hennion & Walsh Asset Management Inc. Purchases 161,910 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
Hennion & Walsh Asset Management Inc. significantly increased its stake in Arcturus Therapeutics Holdings Inc. by purchasing an additional 161,910 shares, bringing its total ownership to 240,303 shares valued at approximately $1.47 million. Despite some analysts lowering price targets, Arcturus Therapeutics maintains a "Moderate Buy" consensus rating with an average target of $29.50. The biotechnology company, trading at around $7.85, recently reported a Q4 earnings miss with ($1.03) EPS and $7.2M in revenue, while institutional investors hold a substantial 94.54% of its shares.
ARCT SEC Filings - Arcturus Therape 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Arcturus Therapeutics Holdings Inc. (ARCT) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms. It highlights recent filings detailing the launch of KOSTAIVE, its approval in Japan, and insider share purchases. The platform uses AI to summarize lengthy reports and provides real-time EDGAR updates.
Arcturus Therapeutics Holdings (ARCT) price target decreased by 27.17% to 25.78
This article reports a significant 27.17% decrease in the price target for Arcturus Therapeutics Holdings (ARCT), bringing it down to $25.78. This change indicates a potentially revised outlook on the company's future stock performance.
Arcturus Therapeutics Holdings (ARCT) price target decreased by 27.17% to 25.78
This article reports that the price target for Arcturus Therapeutics Holdings (ARCT) has been decreased by 27.17% to $25.78. No further details or context regarding this change are provided within the article.
BTIG Maintains Arcturus Therapeutics Holdings (ARCT) Buy Recommendation
BTIG has reiterated its Buy rating on Arcturus Therapeutics Holdings (ARCT). While specific details of the analyst's price target or reasoning are not provided in this snippet, the endorsement suggests continued confidence in the company's prospects. This maintenance of a positive rating could influence investor sentiment and potentially impact ARCT's stock performance.
Arcturus Therapeutics Holdings (ARCT) price target decreased by 27.17% to 25.78
This article reports a significant decrease in the price target for Arcturus Therapeutics Holdings (ARCT). The new price target is set at $25.78, representing a 27.17% reduction from its previous valuation.
Cathie Wood’s ARK sells Nvidia stock, buys Arcturus Therapeutics
Cathie Wood's ARK ETFs made significant trades on Friday, March 27th, 2026, selling off shares in technology giants like NVIDIA, Meta Platforms, AMD, and Teradyne. Concurrently, ARK increased its holdings in Arcturus Therapeutics, reflecting an active management strategy with reallocations towards emerging technologies and innovative companies. These movements follow earlier sales of Nvidia and Meta stock throughout the week.
Vanguard disaggregates holdings; reports 0 shares — Arcturus (ARCT)
The Vanguard Group has filed an amended Schedule 13G/A, reporting 0 beneficial shares of Arcturus Therapeutics Holdings Inc. (ARCT) following an internal realignment effective January 12, 2026. This filing indicates a procedural compliance shift where certain Vanguard subsidiaries will now report their beneficial ownership separately, rather than a market action involving the sale or purchase of ARCT stock. The change is in accordance with SEC Release No. 34-39538, clarifying that Vanguard no longer has beneficial ownership over securities held by these disaggregated units.
Understanding the Setup: (ARCT) and Scalable Risk
This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), highlighting a mid-channel oscillation pattern and a strong risk-reward short setup. It describes institutional trading strategies for various risk profiles, including long, breakout, and short positions, and provides multi-timeframe signal analysis with support and resistance levels.
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf
Arcturus Therapeutics is shifting its focus back to rare disease mRNA therapies after its COVID-19 vaccine received approval in over 30 countries. The company plans to advance its lead programs, ARCT-810 for OTC deficiency and ARCT-032 for cystic fibrosis, by seeking regulatory clarity and initiating further studies. Arcturus has cash runway into Q2 2028 but will require additional non-dilutive funding to complete Phase 3 trials for both programs.
Arcturus Therapeutics stock plunges 50% after weak cystic fibrosis trial data
Arcturus Therapeutics' stock plummeted 50% following the announcement of disappointing Phase 1b interim data for its cystic fibrosis treatment, ARCT-032. The primary endpoint, sweat chloride reduction, showed insufficient improvement compared to placebo, leading to the company's decision not to advance to a Phase 2 study. Despite some positive trends in forced expiratory volume, the overall results halted the development of ARCT-032 for cystic fibrosis and triggered a significant stock decline.
This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday
This article highlights four stock upgrades made by Wall Street analysts. Notably, an HSBC analyst upgraded BP PLC from Reduce to Hold, while analysts also upgraded Chipotle Mexican Grill Inc, Arm Holdings PLC, and SolarEdge Technologies Inc. The report details the specific rating changes and new price targets for each company.
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by B. Riley Financial
B. Riley Financial upgraded Arcturus Therapeutics (NASDAQ:ARCT) to a "strong-buy" rating despite mixed analyst views and recent missed quarterly earnings expectations. The clinical-stage biotech company, focused on mRNA medicines, maintains a "Moderate Buy" consensus rating with a target price of $29.50, and institutional ownership remains high at 94.54%.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Moderate Buy" from Analysts
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received a "Moderate Buy" consensus rating from thirteen brokerage firms, despite recent price target cuts from some analysts. The company's recent quarterly earnings missed expectations, with reported EPS of ($1.03) against an estimate of ($0.92) and revenue of $7.2 million versus an expected $14.32 million. Institutional investors own approximately 94.54% of the stock, with various firms recently adjusting their stakes.
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Benzinga reports on three significant analyst downgrades for Thursday. Raymond James downgraded Xponential Fitness (NYSE: XPOF) from "Strong Buy" to "Market Perform" after its shares closed at $5.67. Additionally, Evercore ISI Group downgraded CSX Corp (NASDAQ: CSX) from "Outperform" to "In-Line" with a raised price target, and DA Davidson downgraded Life360 (NASDAQ: LIF) from "Buy" to "Neutral" with a lowered price target.
